How much longer can Entresto extend survival?
Entresto (sacubitril/valsartan) is designed to reduce the risk of death in certain forms of heart failure, but the exact “how long” depends on the patient population and what outcome you mean (overall survival vs. time-to-first event vs. heart-failure hospitalizations). The key point is that clinical trials show Entresto improves survival compared with older standard therapy in eligible patients [1].
In which heart-failure patients does Entresto prolong life?
Entresto’s survival benefit is supported for people with chronic heart failure with reduced ejection fraction (HFrEF) (and not for every heart-failure subtype). Eligibility and benefit differ by whether the ejection fraction is reduced and by the patient’s baseline severity [1].
How do trials measure “life prolongation” (and what does that translate to in time)?
Most heart-failure survival results are reported as hazard ratios and time-to-event curves rather than a single number of months/years for everyone. That means you can’t reliably convert the trial results into one universal “X months longer” figure without specifying the exact study, population, and comparator therapy [1].
Does Entresto also reduce death risk, or only hospitalizations?
Entresto does both. In addition to lowering heart-failure hospitalization risk, the pivotal evidence includes reductions in cardiovascular death and/or all-cause mortality endpoints depending on the study population and definition of outcomes [1].
How long is Entresto taken, and does stopping reduce the benefit?
Entresto is typically used as a long-term therapy for chronic heart failure. Stopping treatment generally removes the ongoing risk reduction seen in trials, but the precise effect of discontinuation on “time gained” depends on why it was stopped and the patient’s risk level—data are not captured as a simple “lost months” number for all patients [1].
How to estimate what it could mean for a specific patient
If you’re asking for a practical estimate, the most useful factors are:
- heart-failure type (HFrEF vs other categories),
- baseline severity and current medications,
- kidney function and blood pressure (which affect dose and whether it can be continued),
- and the trial population closest to the patient.
Those details determine whether the survival curve improvement seen in studies is likely to apply to you [1].
If you tell me the patient’s diagnosis (HFrEF vs HFpEF), ejection fraction if known, and whether they’re already on a beta blocker and an ACE inhibitor/ARB/ARNI, I can narrow the likely evidence base more precisely.
Sources
[1] https://www.drugs.com/entresto.html